The high-fat diet-fed mouse -: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes

被引:798
作者
Winzell, MS [1 ]
Ahrén, B [1 ]
机构
[1] Lund Univ, Dept Med, Ctr Biomed, S-22184 Lund, Sweden
关键词
D O I
10.2337/diabetes.53.suppl_3.S215
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study characterizes the high-fat diet-fed mouse as a model for impaired glucose tolerance (IGT) and type 2 diabetes. Female C57BL/6J mice were fed a high-fat diet (58% energy by fat) or a normal diet (11% fat). Body weight was higher in mice fed the high-fat diet already after the first week, due to higher dietary intake in combination with lower metabolic efficiency. Circulating glucose increased after 1 week on high-fat diet and remained elevated at a level of similar to1 mmol/l throughout the 12-month study period. In contrast, circulating insulin increased progressively by time. Intravenous glucose challenge revealed a severely compromised insulin response in association with marked glucose intolerance already after 1 week. To illustrate the usefulness of this model for the development of new treatment, mice were fed an orally active inhibitor of dipeptidyl peptidase-IV (LAF237) in the drinking water (0.3 mg/ ml) for 4 weeks. This normalized glucose tolerance, as judged by an oral glucose tolerance test, in association with augmented insulin secretion. We conclude that the high-fat diet-fed C57BL/6J mouse model is a robust model for IGT and early type 2 diabetes, which may be used for studies on pathophysiology and development of new treatment.
引用
收藏
页码:S215 / S219
页数:5
相关论文
共 25 条
[21]   DIFFERENTIAL-EFFECTS OF FAT AND SUCROSE ON THE DEVELOPMENT OF OBESITY AND DIABETES IN C57BL/6J AND A/J MICE [J].
SURWIT, RS ;
FEINGLOS, MN ;
RODIN, J ;
SUTHERLAND, A ;
PETRO, AE ;
OPARA, EC ;
KUHN, CM ;
REBUFFESCRIVE, M .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (05) :645-651
[22]   Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49) [J].
Turner, RC ;
Cull, CA ;
Frighi, V ;
Holman, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (21) :2005-2012
[23]   1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties [J].
Villhauer, EB ;
Brinkman, JA ;
Naderi, GB ;
Burkey, BF ;
Dunning, BE ;
Prasad, K ;
Mangold, BL ;
Russell, ME ;
Hughes, TE .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (13) :2774-2789
[24]   DIETARY OBESITY IN 9 INBRED MOUSE STRAINS [J].
WEST, DB ;
BOOZER, CN ;
MOODY, DL ;
ATKINSON, RL .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (06) :R1025-R1032
[25]   Downregulation of islet hormone-sensitive lipase during long-term high-fat feeding [J].
Winzell, MS ;
Holm, C ;
Ahrén, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (02) :273-278